ACHV News and Press, Achieve Life Sciences Inc. From 05/25/21

IAC/InterActiveCorp (IAC) -31%.Novan (NOVN) -18% on announcing 1-for-10 reverse stock split.Petros Pharmaceuticals (PTPI) -18%.Achieve Life Sciences (ACHV) -15% on proposing stock offeringLordstown Motors (RIDE) -13% on Q1 earnings releaseCreative Realities (CREX...

Achieve Life Sciences (ACHV) trading 7.9% down after hours on launching a proposed underwritten public offering for offering and selling shares; underwriters granted 30-day option to purchase up to an additional 15% of the shares.Offer size, terms not yet disclosed.Net proceeds to b...

SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / May 24, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced a proposed u...

Achieve Life Sciences, Inc. (ACHV) Q1 2021 Earnings Conference Call May 13, 2021 04:30 PM ET Company Participants Jaime Xinos - Executive Vice President, Commercial John Bencich - Chief Executive Officer Cindy Jacobs - President & Chief Medical Officer Jerry Wan - Principal Accounting Off...

Achieve Life Sciences (ACHV): Q1 GAAP EPS of -$1.30 misses by $0.27.As of March 31, 2021, the company's cash, cash equivalents, and restricted cash was $29.7 million.Press Release For further details see: Achieve Life Sciences EPS misses by $0.27

SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / May 13, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced first quarte...

SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / May 4, 2021 / Achieve Life Sciences, Inc. (Nasdaq:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that it wil...

SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / April 22, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced it will be...

Achieve Life Sciences (ACHV) announces results from Phase 2b ORCA-1 trial in scientific journal Nicotine and Tobacco Research. ORCA-1 evaluated the efficacy and safety of cytisinicline across various dosing schedules in 254 smokers.Subjects treated with cytisinicline had statistically si...

Cytisinicline Up to Five Times More Likely to Result in Smoking Abstinence Compared to Placebo Phase 3 ORCA-2 Trial Currently Enrolling at 16 sites in United States SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / April 14, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinica...